Overview

A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

Status:
COMPLETED

Trial end date:
2025-05-22

Target enrollment:

Participant gender:

Summary

This is a phase 1, prospective, single-center, randomized sequence, double-blind, 2-way crossover, relative bioavailability study in healthy adult subjects comparing Sodium Glycerophosphate Injection (SGP) to Sodium Phosphate Injection (NaP). In this study it is planned to randomize approximately 42 healthy male and female subjects. All study periods will be completed during a single residency, the overall duration of residency will be 11 days (10 nights).

Phase:

PHASE1

Details

Lead Sponsor:

Baxter Healthcare Corporation

Treatments:

alpha-glycerophosphoric acid